Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDMaxCyte Inc Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 2 | -$0.08 | -$0.06 | -$0.08 |
| Q2 2026 | 2 | -$0.11 | -$0.07 | -$0.09 |
| Q3 2026 | 2 | -$0.07 | -$0.07 | -$0.07 |
| Q4 2026 | 1 | -$0.06 | -$0.06 | -$0.06 |
| Q1 2027 | 1 | -$0.08 | -$0.07 | -$0.07 |
| Q2 2027 | 1 | -$0.08 | -$0.07 | -$0.07 |
| Q3 2027 | 1 | -$0.07 | -$0.06 | -$0.07 |
| Q4 2027 | 1 | -$0.06 | -$0.05 | -$0.06 |
MaxCyte Inc Earnings Date And Information
MaxCyte Inc last posted its earnings results on Tuesday, May 12th, 2026. The company reported $-0.04 earnings per share for the quarter, topping analysts' consensus estimates of $-0.1 by $0.06. The company had revenue of 9.65 M for the quarter and had revenue of 33.03 M for the year. MaxCyte Inc has generated $0 earnings per share over the last year ($-0.42 diluted earnings per share) and currently has a price-to-earnings ratio of -3.15. MaxCyte Inc has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
MaxCyte Inc Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/13/2026 | Q1 2026 | N/A | -$0.04 | N/A | $7.28 M | $9.65 M |
| 03/25/2026 | Q4 2025 | N/A | -$0.09 | N/A | $9.08 M | $7.30 M |
| 11/13/2025 | Q3 2025 | N/A | -$0.12 | N/A | $6.83 M | $6.83 M |
| 08/06/2025 | Q2 2025 | -$0.10 | -$0.12 | -0.02 | $9.58 M | $8.51 M |
| 05/08/2025 | Q1 2025 | N/A | -$0.10 | N/A | $9.16 M | $10.39 M |
| 03/11/2025 | Q4 2024 | -$0.12 | -$0.10 | 0.02 | $8.04 M | $8.69 M |
| 11/06/2024 | Q3 2024 | -$0.13 | -$0.11 | 0.02 | $7.46 M | $8.16 M |
| 08/06/2024 | Q2 2024 | -$0.14 | -$0.09 | 0.05 | $7.97 M | $10.43 M |
| 05/07/2024 | Q1 2024 | -$0.14 | -$0.09 | 0.05 | $7.51 M | $11.34 M |
| 03/12/2024 | Q4 2023 | -$0.10 | -$0.05 | 0.05 | N/A | $15.66 M |
| 11/08/2023 | Q3 2023 | -$0.10 | -$0.11 | -0.01 | N/A | $8.00 M |
| 08/09/2023 | Q2 2023 | -$0.10 | -$0.10 | 0 | N/A | $9.04 M |
| 05/10/2023 | Q1 2023 | -$0.11 | -$0.08 | 0.03 | N/A | $8.58 M |
| 03/15/2023 | Q4 2022 | -$0.06 | -$0.03 | 0.03 | N/A | $12.42 M |
| 11/09/2022 | Q3 2022 | -$0.09 | -$0.06 | 0.03 | N/A | $10.64 M |
| 08/10/2022 | Q2 2022 | -$0.08 | -$0.08 | 0 | N/A | $9.61 M |
| 05/09/2022 | Q1 2022 | -$0.07 | -$0.04 | 0.03 | N/A | $11.59 M |
| 03/22/2022 | Q4 2021 | -$0.05 | -$0.05 | 0 | N/A | $10.15 M |
| 11/10/2021 | Q3 2021 | -$0.05 | -$0.03 | 0.02 | N/A | $10.14 M |
| 09/13/2021 | Q2 2021 | -$0.05 | -$0.05 | -0 | N/A | $7.11 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
MaxCyte Inc Earnings: FAQ's
In the previous quarter, MaxCyte Inc (:MXCT) reported $-0.04 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.1 by $0.06.
The conference call for MaxCyte Inc's latest earnings report can be listened to online.
The conference call transcript for MaxCyte Inc's latest earnings report can be read online.
MaxCyte Inc (:MXCT) has a recorded annual revenue of $33.03 M.
MaxCyte Inc (:MXCT) has a recorded net income of $-44,630,000.MaxCyte Inc has generated $-0.42 earnings per share over the last four quarters.
MaxCyte Inc (:MXCT) has a price-to-earnings ratio of -3.15 and price/earnings-to-growth ratio is -0.6.